SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: AdventRX Pharmaceuticals, Inc. (Note: Request metadata listed "Savara Inc", but the filing identifies the registrant as AdventRX Pharmaceuticals, Inc.)
Filing Date: May 2, 2005
Reporting Period: Current report for events occurring on May 2, 2005.
Business Context: The company is reporting on the upcoming announcement of preliminary results for its CoFactor Phase II clinical trial.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
There are no financial material changes reported in this document. The material event is the scheduled disclosure of clinical trial data.
Guidance, Outlook, and Management Commentary
- Upcoming Event: The Company announced it will present preliminary results for its CoFactor Phase II Trial.
- Timing and Venue: Results are scheduled to be published at the ASCO Annual Meeting, held May 13-17, 2005, in Orlando, Florida.
- Exhibits: A press release dated May 2, 2005, detailing this matter is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the actual preliminary results of the CoFactor Phase II Trial once published at the ASCO Annual Meeting.
- Review the full text of the press release filed as Exhibit 99.1 for specific data points not summarized in the 8-K.
- Confirm the company name discrepancy between the request metadata ("Savara Inc") and the filing ("AdventRX Pharmaceuticals, Inc").